Abstract:AbstractBackgroundCompared with immunocompetent patients, immunosuppressed patients have higher morbidity and mortality, a longer duration of viral shedding, more frequent complications, and more antiviral resistance during influenza infections. However, few data on this population in China have been reported. We analysed the clinical characteristics, effects of antiviral therapy, and risk factors for admission to the intensive care unit (ICU) and death in this population after influenza infections and explored the influenza vaccination situation for this population.MethodsWe analysed 111 immunosuppressed inpatients who were infected with influenza virus during the 2015–2020 influenza seasons. Medical data were collected through the electronic medical record system and analysed. Univariate analysis and multivariate logistics analysis were used to identify risk factors.ResultsThe most common cause of immunosuppression was malignancies being treated with chemotherapy (64.0%, 71/111), followed by haematopoietic stem cell transplantation (HSCT) (23.4%, 26/111). The most common presenting symptoms were fever and cough. Dyspnoea, gastrointestinal symptoms and altered mental status were more common in HSCT patients than in patients with immunosuppression due to other causes. Approximately 14.4% (16/111) of patients were admitted to the ICU, and 9.9% (11/111) of patients died. Combined and double doses of neuraminidase inhibitors did not significantly reduce the risk of admission to the ICU or death. Risk factors for admission to the ICU were dyspnoea, coinfection with other pathogens and no antiviral treatment within 48 h. The presence of dyspnoea and altered mental status were independently associated with death. Only 2.7% (3/111) of patients less than 12 months old had received a seasonal influenza vaccine.ConclusionFever and other classic symptoms of influenza may be absent in immunosuppressed recipients, especially in HSCT patients. Conducting influenza virus detection at the first presentation seems to be a good choice for early diagnosis. Clinicians should pay extra attention to immunosuppressed patients with dyspnoea, altered mental status, coinfection with other pathogens and no antiviral treatment within 48 h because these patients have a high risk of severe illness. Inactivated influenza vaccines are recommended for immunosuppressed patients.

Phylogenetic Analysis of HA and NA Genes of Influenza A Viruses in Immunosuppressed Inpatients in Beijing During the 2018–2020 Influenza Seasons

Evolutionary, Genetic, Structural Characterization and Its Functional Implications for the Influenza A (H1N1) Infection Outbreak in India from 2009 to 2017.

Molecular Evolution and Characterization of Hemagglutinin and Neuraminidase of Influenza A(H1N1)pdm09 Viruses Isolated in Beijing, China, During the 2017–2018 and 2018–2019 Influenza Seasons

Phylogenetic Analysis of HA and NA Genes and Clinical Characteristics of the Co-Occurring Mutations in HA and NA of Influenza A(H1N1)pdm09 Viruses During 2015-2017 in Beijing, China

Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing.

Evolution analysis and trend prediction of neuraminidase gene of influenza A/H1N1(09pdm) virus in China from 2009 to 2016

Clinical Characteristics, Risk Factors and Antiviral Treatments of Influenza in Immunosuppressed Inpatients in Beijing During the 2015-2020 Influenza Seasons

Genetic evolution analysis of hemagglutinin and neuraminidase genes of H9N2 avian influenza virus in external environment of some areas of Yunnan Province, China from 2020 to 2023

Genomic Analyses Uncover Evolutionary Features of Influenza A/H3N2 Viruses in Yunnan Province, China, from 2017 to 2022

Genomic evolution of influenza during the 2023-2024 season, the johns hopkins health system

Evolution Analysis of HA and NA Genes of Influenza A(H1N1) Virus in Hangzhou Region During 2009～2011

Clinical characteristics of outpatients with influenza-B-associated pneumonia and molecular evolution of influenza B virus in Beijing, China, during the 2021–2022 influenza season

Variation characteristics of hemagglutinin and neuraminidase of 54 influenza A strains from Beijing during 2012 to 2014

Molecular Characterization of Influenza A(H3N2) Virus in Guangdong Province During 2015-2018

Molecular epidemiology and evolution of influenza A and B viruses during winter 2013-2014 in Beijing, China

Phylogenetic, molecular and drug-sensitivity analysis of HA and NA genes of human H3N2 influenza A viruses in Guangdong, China, 2007-2011.

The Neuraminidase of A(H3N2) Influenza Viruses Circulating Since 2016 is Antigenically Distinct from the A/Hong Kong/4801/2014 Vaccine Strain

Clinical Characteristics, Risk Factors and Antiviral Treatments of Influenza in Immunosuppressed Inpatients in Beijing During the 2015–2020 Influenza Seasons

The Phylodynamics of Seasonal Influenza A/H1N1pdm Virus in China Between 2009 and 2019

Characteristic analysis of NA gene of human influenza viruses (H3N2) isolated from 1996 to 2005 in China]

Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea